Talis Biomedical Corp
TLISDelisted Sep 20, 2024- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001584751
Talis Biomedical Corp was delisted on Sep 20, 2024; its insiders filed their last Form 4 on Sep 9, 2024; 18 institutions reported holding it in 13F filings for Q2 2024, worth $6.84M in total; Greenlight Capital was the only superinvestor holding it.
13F holders, Q3 2024
Institutional positions in Talis Biomedical Corp as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
TLIS is no longer listed, and 13F filings after Q2 2024 list far fewer holders. See Q2 2024
- Institutional holders
- 2
- −15 vs. Q2 2024
- Shares held
- 248.8K
- −536.4K (−68.3%) vs. Q2 2024
- Total value
- $460.4K
- −$6.34M (−93.2%) vs. Q2 2024
- New holders
- 0
- 1 more added
- Sold out
- 15
- 0 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TLIS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $26 |
| Q3 2024 | 2 | $460.4K |
| Q2 2024 | 18 | $6.84M |
| Q1 2024 | 18 | $6.93M |
| Q4 2023 | 18 | $5.93M |
| Q3 2023 | 19 | $4.27M |
| Q2 2023 | 22 | $5.27M |
| Q1 2023 | 22 | $5.76M |
| Q4 2022 | 27 | $5.60M |
| Q3 2022 | 29 | $8.59M |
| Q2 2022 | 35 | $12.1M |
| Q1 2022 | 45 | $23.6M |
| Q4 2021 | 47 | $70.2M |
| Q3 2021 | 38 | $119.2M |
| Q2 2021 | 43 | $184.0M |
| Q1 2021 | 45 | $269.0M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Talis Biomedical Corp; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 248,702 | $460.1K | 0.27% | +205,959+481.9% | Added |
| Steward Partners Investment Advisory, LLC | 147 | $272 | 0.00% | 00.0% | Unchanged |
| Baker Bros. Advisors LP | 0 | $0 | 0.00% | −508,323−100.0% | Sold out |
| DME Capital Management, LPSuperinvestorGreenlight Capital | 0 | $0 | 0.00% | −149,052−100.0% | Sold out |
| Vanguard Group Inc | 0 | $0 | 0.00% | −31,013−100.0% | Sold out |
| Prelude Capital Management, LLC | 0 | $0 | 0.00% | −14,928−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −14,020−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −12,299−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −11,607−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −877−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −87−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −84−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −11−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −3−100.0% | Sold out |
| Qube Research & Technologies Ltd | 0 | $0 | 0.00% | −2−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |